0000000001071923

AUTHOR

L De Luca

showing 7 related works from this author

"Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxa…

2010

BACKGROUND: No differences in response rate (RR), progression-free survival (PFS), overall survival (OS) and quality of life (QoL) were seen in patients randomly treated with biweekly oxaliplatin plus either fluorouracil/folinic acid or capecitabine. METHODS: We investigated the independent effect of baseline clinical characteristics and physical functioning (PF) domain on RR, PFS, and OS in 310 patients who completed the EORTC QLQ-C30 questionnaire. Multivariate analyses stratified by treatment were performed. An exploratory analysis was done by grouping patients with a PF score superior or equal to the highest quartile (n = 111), included between the highest and the lowest quartiles (n = …

AdultMalemedicine.medical_specialtyMultivariate analysisColorectal cancerSettore MED/06 - Oncologia MedicaKaplan-Meier EstimateGastroenterologyDisease-Free SurvivalCapecitabineTreatment Outcome; Prognosis; Aged 80 and over; Male; Retrospective Studies; Randomized Controlled Trials as Topic; Middle Aged; Kaplan-Meier Estimate; Colorectal Neoplasms; Female; Disease-Free Survival; Humans; Quality of Life; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials Phase III as Topic; Aged; Adult; Health Status Indicators; Multicenter Studies as TopicFolinic acidQuality of lifeInternal medicineAntineoplastic Combined Chemotherapy Protocols80 and overmedicineOverall survivalHealth Status IndicatorsHumansMulticenter Studies as TopicClinical TrialsRadiology Nuclear Medicine and imagingneoplasmsmetastatic colorectal canceroxaliplatin physical functioning statusAgedRandomized Controlled Trials as TopicRetrospective StudiesAged 80 and overbusiness.industryHematologyGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurgeryOxaliplatinPhase III as TopicTreatment OutcomeClinical Trials Phase III as TopicOncologyQuartileQuality of LifeFemaleColorectal Neoplasmsbusinessmedicine.drug
researchProduct

La persona nel diritto civile

2011

Settore MED/43 - Medicina Legalecapacità di agire capacità giuridica
researchProduct

Design and synthesis of new 2,3-diaryl-1,3-thiazolidin-4-one HIV-1 RT-inhibitors.

2002

HIV-1 RT-inhibitors
researchProduct

Progettazione di nuovi agenti anti-HIV e individuazione di nuovi lead compound

2002

anti-HIV
researchProduct

Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective,…

2007

OBJECTIVE - It is still controversial whether sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) are equally effective in patients with diabetes. In these patients, multiple individual variables may be responsible for neointimal hyperplasia, thus making difficult the comparison of the two drug-eluting stents (DES). RESEARCH DESIGN AND METHODS - We designed a prospective, randomized study to compare the efficacy in prevention of restenosis of SES and PES, both implanted in the same diabetic patient with multiple de novo coronary artery lesions undergoing elective percutaneous coronary intervention. We enrolled 60 patients with diabetes with at least two significant de novo angi…

MaleSirolimusPaclitaxel-Eluting StentPaclitaxelAntineoplastic AgentsCoronary DiseaseDrug-Eluting StentsMiddle AgedCoronary AngiographySirolimus; Paclitaxel-Eluting Stent; Coronary Artery LesionsAnti-Bacterial AgentsCoronary RestenosisDiabetic Patient.Diabetes Mellitus Type 1Diabetes Mellitus Type 2Coronary Artery LesionsHumansFemalerestenosiProspective StudiesDiabetic AngiopathiesAgedDiabetes care
researchProduct

il danno alla persona

2011

danno biologicoSettore MED/43 - Medicina Legale
researchProduct

Attività clinica : colpa medica e responsabilità professionale

2011

Settore MED/43 - Medicina Legalecolpa medica
researchProduct